Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor
- PMID: 25591810
- DOI: 10.1038/cgt.2014.69
Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor
Abstract
T cells can be reprogrammed to redirect specificity to tumor-associated antigens (TAAs) through the enforced expression of chimeric antigen receptors (CARs). The prototypical CAR is a single-chain molecule that docks with TAA expressed on the cell surface and, in contrast to the T-cell receptor complex, recognizes target cells independent of human leukocyte antigen. The bioprocessing to generate CAR(+) T cells has been reduced to clinical practice based on two common steps that are accomplished in compliance with current good manufacturing practice. These are (1) gene transfer to stably integrate the CAR using viral and nonviral approaches and (2) activating the T cells for proliferation by crosslinking CD3 or antigen-driven numeric expansion using activating and propagating cells (AaPCs). Here, we outline our approach to nonviral gene transfer using the Sleeping Beauty system and the selective propagation of CD19-specific CAR(+) T cells on AaPCs.
Similar articles
-
Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells.PLoS One. 2013 May 31;8(5):e64138. doi: 10.1371/journal.pone.0064138. Print 2013. PLoS One. 2013. PMID: 23741305 Free PMC article.
-
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.J Clin Invest. 2016 Sep 1;126(9):3363-76. doi: 10.1172/JCI86721. Epub 2016 Aug 2. J Clin Invest. 2016. PMID: 27482888 Free PMC article. Clinical Trial.
-
Sleeping beauty system to redirect T-cell specificity for human applications.J Immunother. 2013 Feb;36(2):112-23. doi: 10.1097/CJI.0b013e3182811ce9. J Immunother. 2013. PMID: 23377665 Free PMC article.
-
A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19.Immunol Rev. 2014 Jan;257(1):181-90. doi: 10.1111/imr.12137. Immunol Rev. 2014. PMID: 24329797 Free PMC article. Review.
-
Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells.Cancer Gene Ther. 2015 Mar;22(2):79-84. doi: 10.1038/cgt.2015.5. Epub 2015 Feb 13. Cancer Gene Ther. 2015. PMID: 25675873 Review.
Cited by
-
CAR-T cell potency: from structural elements to vector backbone components.Biomark Res. 2022 Sep 19;10(1):70. doi: 10.1186/s40364-022-00417-w. Biomark Res. 2022. PMID: 36123710 Free PMC article. Review.
-
Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions.Front Bioeng Biotechnol. 2022 Jun 22;10:797440. doi: 10.3389/fbioe.2022.797440. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 35814023 Free PMC article. Review.
-
piggyBac system to co-express NKG2D CAR and IL-15 to augment the in vivo persistence and anti-AML activity of human peripheral blood NK cells.Mol Ther Methods Clin Dev. 2021 Nov 4;23:582-596. doi: 10.1016/j.omtm.2021.10.014. eCollection 2021 Dec 10. Mol Ther Methods Clin Dev. 2021. PMID: 34853803 Free PMC article.
-
Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.PLoS One. 2016 Aug 22;11(8):e0159477. doi: 10.1371/journal.pone.0159477. eCollection 2016. PLoS One. 2016. PMID: 27548616 Free PMC article.
-
CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities.Cell Oncol (Dordr). 2021 Jun;44(3):495-523. doi: 10.1007/s13402-021-00593-1. Epub 2021 Mar 24. Cell Oncol (Dordr). 2021. PMID: 33759063 Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources